Antibiotics as immunomodulant agents in COPD

Current Opinion in Pharmacology

Volumn 12, Issue 3, 2012, Pages 293-299

  Blasi, Francesco ^a   Mantero, Marco ^a   Aliberti, Stefano ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; CLARITHROMYCIN; CSY 0073; EM 703; EM 900; ERYTHROMYCIN DERIVATIVE; MACROLIDE; QUINOLONE; TOBRAMYCIN; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LOW DRUG DOSE; LUNG ALVEOLUS MACROPHAGE; LUNG EMPHYSEMA; NEUTROPHIL; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; QUORUM SENSING; RISK ASSESSMENT; RISK FACTOR; UNSPECIFIED SIDE EFFECT;

EID: 84862276427     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2012.01.006     Document Type: Review

References (77)

1. D.M. Mannino, and A.S. Buist Global burden of COPD: risk factors, prevalence, and future trends Lancet 370 2007 765 773
2. D.E. Bloom, E.T. Cafiero, E. Jané-Llopis, S. Abrahams-Gessel, L.R. Bloom, S. Fathima, A.B. Feigl, T. Gaziano, M. Mowafi, and A. Pandya The Global Economic Burden of Non-communicable Diseases 2011 World Economic Forum Geneva www.weforum.org/EconomicsOfNCD
3. B.G. Cosio, and A. Agusti Update in chronic obstructive pulmonary disease 2009 Am J Respir Crit Care Med 181 2010 655 660
4. M.K. Han Update in chronic obstructive pulmonary disease 2010 Am J Respir Crit Care Med 183 2011 1311 1315
5. J.C. Hogg, and W. Timens The pathology of chronic obstructive pulmonary disease Annu Rev Pathol 4 2009 435 459
6. J. Araya, S. Cambier, J.A. Markovics, P. Wolters, D. Jablons, A. Hill, W. Finkbeiner, K. Jones, V.C. Broaddus, and D. Sheppard Squamous metaplasia amplifies pathologic epithelial-mesenchymal interactions in COPD patients J Clin Invest 28 2007 3551 3562
7. C.K. Andersson, M. Mori, L. Bjermer, C.G. Lofdahl, and J.S. Erjefalt Alterations in lung mast cell populations in patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 181 2010 206 217
8. I. Cerveri, and V. Brusasco Revisited role for mucus hypersecretion in the pathogenesis of COPD Eur Respir Rev 19 2010 109 112
9. K. Ito, M. Ito, W.M. Elliott, B. Cosio, G. Caramori, O.M. Kon, A. Barczyk, S. Hayashi, I.M. Adcock, and J.C. Hogg Decreased histone deacetylase activity in chronic obstructive pulmonary disease N Engl J Med 352 2005 1967 1976
10. B.G. Cosio, L. Tsaprouni, K. Ito, E. Jazrawi, I.M. Adcock, and P.J. Barnes Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages J Exp Med 200 2004 689 695
11. A. Zanini, A. Chetta, M. Saetta, S. Baraldo, C. Castagnetti, G. Nicolini, M. Neri, and D. Olivieri Bronchial vascular remodelling in patients with COPD and its relationship with inhaled steroid treatment Thorax 64 2009 1019 1024
12. C. Tubby, T. Harrison, I. Todd, and L. Fairclough Immunological basis of reversible and fixed airways disease Clin Sci 121 2011 285 296
13. F. Polverino, S. Baraldo, E. Bazzan, S. Agostini, G. Turato, F. Lunardi, E. Balestro, M. Damin, A. Papi, and P. Maestrelli A novel insight into adaptive immunity in chronic obstructive pulmonary disease: B cell activating factor belonging to the tumor necrosis factor family Am J Respir Crit Care Med 182 2010 1011 1019
14. C.M. Greene, T.B. Low, S.J. O'Neill, and N.G. McElvaney Anti-proline-glycineproline or antielastin autoantibodies are not evident in chronic inflammatory lung disease Am J Respir Crit Care Med 181 2010 31 35
15. P.J. Barnes New therapies for chronic obstructive pulmonary disease Med Princ Pract 19 2010 330 338
16. J. Vestbo, E. Prescott, and P. Lange Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group Am J Crit Care Med 153 1996 1530 1535
17. R. de Marco, S. Accordini, I. Cerveri, A. Corsico, J.M. Antó, N. Künzli, C. Janson, J. Sunyer, D. Jarvis, and S. Chinn Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm Am J Respir Crit Care Med 175 2007 32 39
18. R. Kohansal, P. Martinez-Camblor, A. Agusti, A.S. Buist, D.M. Mannino, and J.B. Soriano The natural history of chronic airflow obstruction revisited: an analysis of the Framingham offspring cohort Am J Respir Crit Care Med 180 2009 3 10
19. D. Banerjee, O.A. Khair, and D. Honeybourne The effect of oral clarithromycin on health status and sputum bacteriology in stable COPD Respir Med 99 2005 208 215
20. T.A. Seemungal, T.M. Wilkinson, and J.R. Hurst Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations Am J Respir Crit Care Med 178 2008 1139 1147
21. F. Blasi, D. Bonardi, S. Aliberti, P. Tarsia, M. Confalonieri, O. Amir, M. Carone, F. Di Marco, S. Centanni, and E. Guffanti Long term azithromycin use in patients with chronic obstructive pulmonary disease and tracheostomy Pulm Pharmacol Ther 23 2010 200 207
22. R.K. Albert, J. Connett, W.C. Bailey, R. Casaburi, J.A. Cooper Jr., G.J. Criner, J.L. Curtis, M.T. Dransfield, M.K. Han, and S.C. Lazarus Azithromycin for prevention of exacerbations of COPD N Engl J Med 365 2011 689 698
23. S. Sethi, P.W. Jones, M.S. Theron, M. Miravitlles, E. Rubinstein, J.A. Wedzicha, and R. Wilson Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial Respir Res 11 2010 10
24. S. Sethi, C. Wrona, B.J. Grant, and T.F. Murphy Strain-specific immune response to Haemophilus influenzae in chronic obstructive pulmonary disease Am J Respir Crit Care Med 169 2004 448 453
25. C.S. Berenson, M.A. Garlipp, L.J. Grove, J. Maloney, and S. Sethi Impaired phagocytosis of nontypeable Haemophilus influenzae by human alveolar macrophages in chronic obstructive pulmonary disease J Infect Dis 194 2006 1375 1384
26. D.C. Look, C.L. Chin, L.J. Manzel, E.E. Lehman, A.L. Humlicek, L. Shi, T.D. Starner, G.M. Denning, T.F. Murphy, and S. Sethi Modulation of airway inflammation by Haemophilus influenzae isolates associated with chronic obstructive pulmonary disease exacerbation Proc Am Thorac Soc 3 2006 482 483
27. L. Wu, J.M. Skinner, N. Lambie, J.C. Vuletic, F. Blasi, and P.N. Black Immunohistochemical staining for Chlamydia pneumoniae is increased in lung tissue from subjects with chronic obstructive pulmonary disease Am J Respir Crit Care Med 162 2000 1148 1151
28. F. Blasi, S. Damato, R. Cosentini, P. Tarsia, R. Raccanelli, S. Centanni, and L. Allegra Chlamydia pneumoniae and chronic bronchitis: association with severity and bacterial clearance following treatment Thorax 57 2002 672 676
29. T. Kikuchi, K. Hagiwara, Y. Honda, K. Gomi, T. Kobayashi, H. Takahashi, Y. Tokue, A. Watanabe, and T. Nukiwa Clarithromycin suppresses lipopolysaccharide-induced interleukin-8 production by human monocytes through AP-1 and NF-kappa B transcription factors J Antimicrob Chemother 49 2002 745 755
30. M. Desaki, H. Takizawa, T. Ohtoshi, T. Kasama, K. Kobayashi, T. Sunazuka, S. Omura, K. Yamamoto, and K. Ito Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells Biochem Biophys Res Commun 267 2000 124 128
31. V. Asgrimsson, T. Gudjonsson, G.H. Gudmundsson, and O. Baldursson Novel effects of azithromycin on tight junction proteins in human airway epithelia Antimicrob Agents Chemother 50 2006 1805 1812
32. C. Feldman, R. Anderson, A.J. Theron, G. Ramafi, P.J. Cole, and R. Wilson Roxithromycin, clarithromycin, and azithromycin attenuate the injurious effects of bioactive phospholipids on human respiratory epithelium in vitro Inflammation 21 1997 655 665
33. R. Anderson, A.J. Theron, and C. Feldman Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils Inflammation 20 1996 693 705
34. M.J. Sanz, Y.N. Nabah, M. Cerdá-Nicolás, J.E. O'Connor, A.C. Issekutz, J. Cortijo, and E.J. Morcillo Erythromycin exerts in vivo anti-inflammatory activity downregulating cell adhesion molecule expression Br J Pharmacol 144 2005 190 201
35. M. Millrose, M. Krause, B. Flick, and R. Stahlmann Effects of macrolides on proinflammatory epitopes on endothelial cells in vitro Arch Toxicol 83 2009 469 476
36. M. Vrančić, M. Banjanac, K. Nujić, M. Bosnar, T. Murati, V. Munić, D.S. Polančec, D. Belamarić, M.J. Parnham, and V.E. Haber Azithromycin distinctively modulates classical activation of human monocytes in vitro Br J Pharmacol 4 2011 10.1111/j.1476-5381.2011.01576.x [Epub ahead of print]
37. S. Sethi, P. Mallia, and S.L. Johnston New paradigms in the pathogenesis of chronic obstructive pulmonary disease II Proc Am Thorac Soc 6 2009 532 534
38. S. Hodge, G. Hodge, S. Brozyna, H. Jersmann, M. Holmes, and P.N. Reynolds Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages Eur Respir J 28 2006 486 495
39. D.J. Feola, B.A. Garvy, T.J. Cory, S.E. Birket, H. Hoy, D. Hayes, and B.S. Murphy Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas Antimicrob Agents Chemother 54 2010 2437 2447
40. S. Hodge, G. Hodge, H. Jersmann, G. Matthews, J. Ahern, M. Holmes, and P.N. Reynolds Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease Am J Respir Crit Care Med 178 2008 139 148
41. M.E. Muroski, M.D. Roycik, R.G. Newcomer, P.E. Van den Steen, G. Opdenakker, H.R. Monroe, Z.J. Sahab, and Q.X. Sang Matrix metalloproteinase-9/ gelatinase B is a putative therapeutic target of chronic obstructive pulmonary disease and multiple sclerosis Curr Pharm Biotechnol 9 2008 34 46
42. A. Churg, R. Wang, X. Wang, P.O. Onnervik, K. Thim, and J.L. Wright Effect of an MMP-9/MMP-12 inhibitor on smoke-induced emphysema and airway remodelling in guinea pigs Thorax 62 2007 706 713
43. S. Molet, C. Belleguic, H. Lena, N. Germain, C.P. Bertrand, S.D. Shapiro, J.M. Planquois, P. Delaval, and V. Lagente Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease Inflamm Res 54 2005 31 36
44. Y. Nakanishi, D. Kobayashi, Y. Asano, T. Sakurai, M. Kashimura, S. Okuyama, Y. Yoneda, S.D. Shapiro, and K. Takayama Clarithromycin prevents smoke-induced emphysema in mice Am J Respir Crit Care Med 179 2009 271 278
45. W.C. Tsai, M.L. Rodriguez, K.S. Young, J.C. Deng, V.J. Thannickal, K. Tateda, M.B. Hershenson, and T.J. Standiford Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection Am J Respir Crit Care Med 170 2004 1331 1339
46. S. Kusano, J. Kadota, S. Kohno, K. Iida, K. Kawakami, T. Morikawa, and K. Hara Effect of roxithromycin on peripheral neutrophil adhesion molecules in patients with chronic lower respiratory tract disease Respiration 62 1995 217 222
47. H. Levert, B. Gressier, I. Moutard, C. Brunet, T. Dine, M. Luyckx, M. Cazin, and J.C. Cazin Azithromycin impact on neutrophil oxidative metabolism depends on exposure time Inflammation 22 1998 191 201
48. T. Morikawa, J.I. Kadota, S. Kohno, and T. Kondo Superoxide dismutase in alveolar macrophages from patients with diffuse panbronchiolitis Respiration 67 2000 546 551
49. K. Kawakami, J. Kadota, K. Iida, T. Fujii, R. Shirai, Y. Matsubara, and S. Kohno Phenotypic characterization of T cells in bronchoalveolar lavage fluid (BALF) and peripheral blood of patients with diffuse panbronchiolitis: the importance of cytotoxic T cells Clin Exp Immunol 107 1997 410 416
50. J. Kadota, S. Mizunoe, K. Kishi, I. Tokimatsu, H. Nagai, and M. Nasu Antibiotic-induced apoptosis in human activated peripheral lymphocytes Int J Antimicrob Agents 25 2005 216 220
51. K. Sugiyama, R. Shirai, H. Mukae, H. Ishimoto, T. Nagata, N. Sakamoto, H. Ishii, S. Nakayama, K. Yanagihara, Y. Mizuta, and S. Kohno Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells Clin Exp Immunol 147 2007 540 546
52. Y. Morinaga, K. Yanagihara, N. Miyashita, M. Seki, K. Izumikawa, H. Kakeya, Y. Yamamoto, H. Mukae, Y. Yamada, S. Kohno, and S. Kamihira Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells Pulm Pharmacol Ther 22 2009 580 586
53. U.H. Ha, J.H. Lim, H.J. Kim, W. Wu, S. Jin, H. Xu, and J.D. Li MKP1 regulates the induction of MUC5AC mucin by Streptococcus pneumoniae pneumolysin by inhibiting the PAK4-JNK signaling pathway J Biol Chem 283 2008 30624 30631
54. N. Araki, K. Yanagihara, Y. Morinaga, K. Yamada, S. Nakamura, Y. Yamada, S. Kohno, and S. Kamihira Azithromycin inhibits nontypeable Haemophilus influenzae-induced MUC5AC expression and secretion via inhibition of activator protein-1 in human airway epithelial cells Eur J Pharmacol 644 2010 209 214
55. M. Kraft, K.B. Adler, J.L. Ingram, A.L. Crews, T.P. Atkinson, C.B. Cairns, D.C. Krause, and H.W. Chu Mycoplasma pneumoniae induces airway epithelial cell expression of MUC5AC in asthma Eur Respir J 31 2008 43 46
56. E. Tagaya, J. Tamaoki, M. Kondo, and A. Nagai Effect of a short course of clarithromycin therapy on sputum production in patients with chronic airway hypersecretion Chest 122 2002 213 218
57. - currents by 14-membered macrolide antibiotics in isolated acinar cells of the guinea pig nasal gland Am J Respir Cell Mol Biol 13 1995 449 454
58. I.E. Rascon-Aguilar, M. Pamer, P. Wludyka, J. Cury, D. Coultas, L.R. Lambiase, N.S. Nahman, and K.J. Vega Role of gastroesophageal reflux symptoms in exacerbations of COPD Chest 130 2006 1096 1101
59. V. Mertens, BlondeauK, A. Pauwels, R. Farre, B. Vanaudenaerde, R. Vos, G. Verleden, D.E. Van Raemdonck, L.J. Dupont, and D. Sifrim Azithromycin reduces gastroesophageal reflux and aspiration in lung transplant recipients Dig Dis Sci 54 2009 972 979
60. M. Fraderix, and A.J. Downie Quorum sensing: regulating the regulators Adv Microb Physiol 58 2011 23 80
61. J.S. Dickschat Quorum sensing and bacterial biofilms Nat Prod Rep 27 2010 343 369
62. M.J. Gambello, and B.H. Iglewski Cloning and characterization of the Pseudomonas aeruginosa lasR gene, a transcriptional activator of elastaseexpression J Bacteriol 173 1991 3000 3009
63. A. Latifi, M.K. Winson, M. Foglino, B.W. Bycroft, G.S. Stewart, A. Lazdunski, and P. Williams Multiple homologues of LuxR and LuxI control expression of virulence determinants and secondary metabolites through quorum sensing in Pseudomonas aeruginosa PAO1 Mol Microbiol 17 1995 333 343
64. J. Rocha-Estrada, A.E. Aceves-Diez, G. Guarneros, and M. de la Torre The RNPP family of quorum-sensing proteins in Gram-positive bacteria Appl Microbiol Biotechnol 87 2010 913 923
65. M.E. Shindersoe, M. Alhede, R. Phipps, L. Yang, P.O. Jensen, T.B. Rasmussen, T. Bjarnsholt, T. Tolker-Nielsen, N. Hoiby, and M. Givskov Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother 52 2008 3648 3663
66. Y. Imamura, Y. Higashiyama, K. Kazunori, K. Izumikawa, K. Yanagihara, H. Ohno, Y. Miyazaki, Y. Hirakata, Y. Mizuta, and J. Kadota Azithromycin exhibits bactericidal effects on Pseudomonas aeruginosa through interaction with the outer membrane Antimicrob Agents Chemother 49 2005 1377 1380
67. X. Mulet, M.D. Macia, A. Mena, C. Juan, J.L. Perez, and A. Oliver Azithromycin in Pseudomonas aeruginosa biofilms: bacericidal activity and selection of nfxB mutants Antimicrob Agents Chemother 53 2009 1552 1560
68. I. Shalit, L. Horev-Azaria, I. Fabian, H. Blau, N. Kariv, I. Shechtman, H. Alteraz, and Kletter Y. Immunomodulatory Protective effects of moxifloxacin against Candida albicans-induced bronchopneumonia in mice injected with cyclophosphamide Antimicrob Agents Chemother 46 2002 2442 2449
69. H. Blau, K. Klein, I. Shalit, D. Halperin, and I. Fabian Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kB activation in a cystic fibrosis epithelial cell line Am J Physiol Lung Cell Mol Physiol 292 2007 L343 L352
70. A. Dalhoff, and I. Shalit Immunomodulatory effects of quinolones Lancet Infect Dis 3 2003 359 371
71. M.E. Skindersoe, M. Alhede, R. Phipps, L. Yang, P.O. Jensen, T.B. Rasmussen, T. Bjarnsholt, T. Tolker-Nielsen, N. Hoiby, and M. Givskov Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother 52 2008 3648 3663
72. R. Dal Negro, C. Micheletto, S. Tognella, M. Visconti, and C. Turati Tobramycin Nebulizer solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation Adv Ther 25 2008 1019 1030
73. J. Cazalis, S. Tanabe, and G. Gagnon Tetracyclines and chemically modified tetracycline-3 (CMT-3) modulate cytokine secretion by lipopolysaccharide-stimulated whole blood Inflammation 32 2009 130 137
74. H. Gouda, T. Sunazuka, K. Yoshida, A. Sugawara, Y. Sakoh, S. Omura, and S. Hirono Three-dimensional solution structure of EM703 with potent promoting activity of monocyte-to-macrophage differentiation Bioorg Med Chem Lett 16 2006 2496 2499
75. A. Sugawara, A. Sueki, T. Hirose, K. Nagai, H. Gouda, S. Hirono, H. Shima, K.S. Akagawa, S. Omura, and T. Sunazuka Novel 12-membered non-antibiotic macrolides from erythromycin A; EM900 series as novel leads for anti-inflammatory and/or immunomodulatory agents Bioorg Med Chem Lett 21 2011 3373 3376
76. K. Otsu, H. Ishinaga, S. Suzuki, A. Sugawara, T. Sunazuka, S. Omura, H. Jono, and K. Takeuchi Effects of a novel nonantibiotic macrolide, EM900, on cytokine and mucin gene expression in a human airway epithelial cell line Pharmacology 88 2011 327 332
77. A. Mencarelli, E. Distrutti, B. Renga, S. Cipriani, G. Palladino, C. Booth, G. Tudor, J.H. Guse, U. Hahn, M. Burnet, and S. Fiorucci Development of non-antibiotic macrolide that corrects inflammation-driven immune dysfunction in models of inflammatory bowel diseases and arthritis Eur J Pharmacol 665 2011 29 39